Immuneel Therapeutics launches global CAR T-cell therapy for Non-Hodgkin’s Lymphoma in India – Healthcare News

Immuneel Therapeutics on Monday launched Qartemi, a CAR T-cell therapy for adult B-cell Non-Hodgkin Lymphoma (B-NHL). According to the company’s statement, it is personalized therapy for adult patients with relapsed or refractory B-NHL.
The company aims to address a critical gap in India’s cancer immunotherapy landscape. This groundbreaking therapy—benchmarked to global standards—is now available locally, offering renewed hope to patients for whom conventional therapies including chemotherapy prove ineffective, it claimed.
India faces a rising burden of blood cancers, with around 120,000 new cases and over 70,000 deaths annually from leukemia, lymphoma, and multiple myeloma. Amidst the increasing incidence of blood cancer cases, Qartemi—a pioneering CAR-T cell therapy from Immuneel Therapeutics—stands as a lifeline, representing the need for advanced treatment in CAR-T therapy becomes increasingly critical.
“Since Immuneel’s inception in 2019, our mission has been to offer affordable and innovative, lifesaving therapies for cancer that are otherwise inaccessible. With Qartemi, our flagship CAR T-cell therapy, we aim to transform cancer treatment in India by providing globally advanced, personalized therapies at an affordable cost. Designed to improve patient outcomes, Qartemi exemplifies our commitment to positioning India as a leader in next-generation, transformative therapies,” Kiran Mazumdar-Shaw, Board Director & Co-Founder, Immuneel Therapeutics said.
Meanwhile, Dr. Siddhartha Mukherjee, Board Director & Co-Founder, Immuneel Therapeutics, said that the launch of Qartemi marks a pivotal moment in India’s fight against cancer.
“By combining world-class research CAR-T cell therapy with indigenous manufacturing, we are offering new hope to patients facing aggressive blood cancers. By bringing globally benchmarked CAR-T cell therapy to India, we are not only providing a breakthrough treatment but also redefining what is possible in precision medicine. This is a critical step in ensuring that advanced, life-saving therapies are within reach for patients who need them most,” Dr. Mukherjee said.
Immuneel initiated India’s first CAR T cell therapy trial in 2022 for a novel autologous CD19 directed CAR-T cell therapy in patients with relapsed/refractory B cell malignancies.
Immuneel has partnered with leading hospitals, including Narayana Health, Apollo Hospitals, CMC Vellore & Ludhiana, Manipal Hospitals, RGCIRC Delhi, SGPGI Lucknow, Amrita Hospital Faridabad, HOC Vedanta Ahmedabad, Cytecare Bangalore, Sparsh Bangalore, Marengo Asia Hospitals among others, to provide Qartemi to their patients, the company claimed in its statement.
link